Anúncio
Anúncio

STOK

STOK logo

Stoke Therapeutics, Inc. Common Stock

32.85
USD
Patrocinado
-0.83
-2.45%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

33.03

+0.18
+0.55%

Relatórios de Lucros STOK

Rácio de surpresa positiva

STOK separação 17 de 26 últimas estimativas.

65%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.95M
/
-$0.73
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-44.04%
/
+12.31%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-73.69%
/
+305.56%

Stoke Therapeutics, Inc. Common Stock earnings per share and revenue

On 04 de nov. de 2025, STOK reported earnings of -0.65 USD per share (EPS) for Q3 25, missing the estimate of -0.57 USD, resulting in a -12.13% surprise. Revenue reached 10.63 milhão, compared to an expected 6.28 milhão, with a 69.21% difference. The market reacted with a -9.94% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of -0.73 USD, with revenue projected to reach 5.95 milhão USD, implying an aumentar of 12.31% EPS, and diminuir of -44.04% in Revenue from the last quarter.
FAQ
For Q3 2025, Stoke Therapeutics, Inc. Common Stock reported EPS of -$0.65, missing estimates by -12.13%, and revenue of $10.63M, 69.21% above expectations.
The stock price moved down -9.94%, changed from $25.34 before the earnings release to $22.82 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 13 analistas, Stoke Therapeutics, Inc. Common Stock is expected to report EPS of -$0.73 and revenue of $5.95M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio